Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
A report from Bloomberg released in the last half an hour has stated that AstraZeneca (LON: AZN) will conduct an additional trial to assess its Covid-19 vaccine after questions were raised regarding its recent results.
The drugmaker had been pushing back this week after experts began to question its results that were published earlier this week.
Doubts about the vaccine occurred after the company began to probe a mistake into why the accidental use of a half dosage resulted in a higher efficacy rate.
Bloomberg said that the new trial will run instead of adding an arm to an ongoing trial in the US and it will evaluate a lower dosage that performed better than the full amount in its most recent studies.
AstraZeneca’s CEO, Pascal Soriot, said that now they have found a better efficacy it will need to validate it and as a result, needs to conduct an additional study.
According to the report, it will more than likely be another international study, with Soriot saying that it “could be faster because we know the efficacy is high so we need a smaller number of patients.”
London-listed shares of AstraZeneca are trading at 7796p, down 0.06% on Thursday.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .